Shaemus Gleason

Shaemus joined the Company in May 2021 and is the Company’s Executive Vice President of US Operations.

Shaemus has over 13 years of experience spanning across all facets of targeted radionuclide therapies and diagnostic radiopharmaceuticals. Prior to joining the Company, Shaemus was a member of the oncology strategy business unit at Bayer/Algeta where he was responsible for the technical operations in their phase he targeted alpha therapy development globally. Prior to this, he held a leadership role on the US commercial organisation supporting a marketed product Xofigo® (radium-223 dichloride) for metastatic prostate cancer.